Acetazolamide Sodium

Familial periodic paralysis, Calorimetry, Indirect, Hypercapnia + 12 more
Treatment
5 FDA approvals
20 Active Studies for Acetazolamide Sodium

What is Acetazolamide Sodium

AcetazolamideThe Generic name of this drug
Treatment SummaryAcetazolamide is a medication sometimes used to help treat seizure disorders, particularly absence seizures. It can also be used as an additional treatment for tonic-clonic, myoclonic, and atonic seizures, especially in women whose seizures are triggered by the menstrual cycle. However, the effects of acetazolamide can quickly wear off due to tolerance. The antiepileptic effect of this drug is thought to be due to its ability to inhibit brain carbonic anhydrase, which increases chloride levels in the brain and increases inhibition.
AcetaZOLAMIDEis the brand name
Acetazolamide Sodium Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
AcetaZOLAMIDE
Acetazolamide
1978
96

Approved as Treatment by the FDA

Acetazolamide, commonly known as AcetaZOLAMIDE, is approved by the FDA for 5 uses such as Open Angle Glaucoma (OAG) and Other and unspecified effects of high altitude .
Open Angle Glaucoma (OAG)
Other and unspecified effects of high altitude
Altitude Sickness
Open Angle Glaucoma
nonuveitic secondary glaucoma

Effectiveness

How Acetazolamide Sodium Affects PatientsAcetazolamide is a medicine used to reduce the amount of fluid in the body, treat certain types of seizures, and increase urination. It is not a type of antibiotic, but instead belongs to a group of drugs called sulfonamides. It works differently than other medications and has a unique chemical structure and effect on the body.
How Acetazolamide Sodium works in the bodyAcetazolamide works in two main ways. First, it reduces the amount of carbon dioxide in the lungs, which increases the amount of oxygen in your blood. Second, it stops a chemical reaction that helps the body absorb hydrogen ions. This affects the way that salt and water are passed out of your body in urine, making you pass more water than usual.

When to interrupt dosage

The measure of Acetazolamide Sodium is contingent upon the identified disorder, including Inflammation, Tonic - clonic seizures and Metabolic Alkalosis. The dosage amount fluctuates according to the method of delivery (e.g. Injection, powder, lyophilized, for solution - Intravenous or Powder, for solution) specified in the table beneath.
Condition
Dosage
Administration
Respiration stimulated
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Urine alkalinization therapy
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Congestive Heart Failure
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Preoperative
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Metabolic Alkalosis
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Open Angle Glaucoma
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Hypercapnia
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
nonuveitic secondary glaucoma
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Swollen feet or ankles
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Familial periodic paralysis
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Calorimetry, Indirect
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Altitude Sickness
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Kidney Calculi
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
salicylate intoxication
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule
Edema
, 500.0 mg, 250.0 mg, 500.0 mg/mL, 125.0 mg
, Capsule, extended release, Oral, Capsule, extended release - Oral, Tablet, Tablet - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Capsule - Oral, Capsule

Warnings

Acetazolamide Sodium Contraindications
Condition
Risk Level
Notes
Acidosis
Do Not Combine
Angle Closure Glaucoma
Do Not Combine
Disease
Do Not Combine
Cirrhosis
Do Not Combine
depressed sodium and/or potassium blood serum levels
Do Not Combine
Glaucoma
Do Not Combine
Sulfonamides
Do Not Combine
Chronic Kidney Disease (CKD)
Do Not Combine
hyperchloremic acidosis
Do Not Combine
Glaucoma
Do Not Combine
Chronic Kidney Disease (CKD)
Do Not Combine
Addison Disease
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Acetazolamide may interact with Pulse Frequency
There are 20 known major drug interactions with Acetazolamide Sodium.
Common Acetazolamide Sodium Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Acetazolamide.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Acetazolamide.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Acetazolamide.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Acetazolamide.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Acetazolamide.

Acetazolamide Sodium Novel Uses: Which Conditions Have a Clinical Trial Featuring Acetazolamide Sodium?

76 active studies are currently being conducted to assess the potential of Acetazolamide Sodium to treat Glaucoma, Preoperative Swelling and other related conditions.
Condition
Clinical Trials
Trial Phases
Hypercapnia
0 Actively Recruiting
Familial periodic paralysis
0 Actively Recruiting
Metabolic Alkalosis
0 Actively Recruiting
Edema
0 Actively Recruiting
Preoperative
0 Actively Recruiting
Calorimetry, Indirect
0 Actively Recruiting
Respiration stimulated
0 Actively Recruiting
Congestive Heart Failure
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2
salicylate intoxication
0 Actively Recruiting
nonuveitic secondary glaucoma
0 Actively Recruiting
Urine alkalinization therapy
0 Actively Recruiting
Altitude Sickness
0 Actively Recruiting
Open Angle Glaucoma
10 Actively Recruiting
Phase 3, Not Applicable, Phase 4
Kidney Calculi
0 Actively Recruiting
Swollen feet or ankles
5 Actively Recruiting
Phase 2, Not Applicable, Phase 4

Patient Q&A Section about acetazolamide sodium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does acetazolamide cause hyponatremia?

"Side effects of acetazolamide can include tingling in the hands and feet, tiredness, drowsiness, depression, decreased sex drive, a bitter or metallic taste in the mouth, nausea, vomiting, stomach cramps, diarrhea, dark stool, increased urination, kidney stones, acidosis (too much acid in the blood), and electrolyte changes (low potassium or sodium levels)."

Answered by AI

Does acetazolamide increase sodium?

"Acetazolamide causes an increase in the loss of sodium and potassium ions into the tubular fluid, which causes urine to become more alkaline. However, the hydrogen ions are retained in the plasma, which causes a mild acidosis. However, the drop in the plasma concentration of hydrogen ions stimulates the activity of carbonic anhydrase, which quickly leads to tolerance to the diuretic action of acetazolamide."

Answered by AI

Does acetazolamide lower sodium?

"Acetazolamide inhibits carbonic anhydrase, causing sodium, bicarbonate, and chloride to be excreted rather than reabsorbed. This also leads to the excretion of excess water."

Answered by AI

What is the use of acetazolamide?

"Acetazolamide is a medication used to treat glaucoma, a condition in which increased pressure in the eye can lead to gradual loss of vision. Acetazolamide works by decreasing the pressure in the eye."

Answered by AI

Clinical Trials for Acetazolamide Sodium

Have you considered Acetazolamide Sodium clinical trials? We made a collection of clinical trials featuring Acetazolamide Sodium, we think they might fit your search criteria.Go to Trials
Image of Future Life Clinical Trials in Miami, United States.

Extended vs Immediate Release Torsemide for Heart Failure

18+
All Sexes
Miami, FL
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. During the study period, participants' current loop diuretics will be replaced with an equivalent dose of either immediate-release or extended-release torsemide. Following a one-week stabilization period on the assigned torsemide formulation, patients will report to the clinical site for an assessment visit. On the study day, patients will take a single dose of the same torsemide formulation they have been on for the past week, administered after breakfast. Urine samples be collected are: * 0-4 hours post-dosing (pre-lunch period) * 4-8 hours post-dosing (post-lunch period) * 8-24 hours post-dosing (24 hours period) The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
Phase 4
Recruiting
Future Life Clinical TrialsSalim Shah, PhD, JDSarfez Pharmaceuticals, Inc.
Have you considered Acetazolamide Sodium clinical trials? We made a collection of clinical trials featuring Acetazolamide Sodium, we think they might fit your search criteria.Go to Trials
Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Recruiting
Has No Placebo
Ronald Reagan UCLA Medical Center
Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN
Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.
Recruiting
Senior-friendly
University of Tennessee Medical Center (+1 Sites)Satya Surbhi, PhD
Image of Brigham and Women's Hospital in Boston, United States.

Care Transitions App for Multiple Chronic Conditions

18+
All Sexes
Boston, MA
The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.
Recruiting
Has No Placebo
Brigham and Women's HospitalLipika Samal, MD, MPH
Have you considered Acetazolamide Sodium clinical trials? We made a collection of clinical trials featuring Acetazolamide Sodium, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security